July 29th 2025
Explore innovative strategies and emerging therapies transforming small cell lung cancer treatment, enhancing patient outcomes and survival rates.
Pembrolizumab/Chemo Appears to Improve Survival in Advanced Mesothelioma
March 13th 2023The final analysis of the phase 2/3 CCTG IND.227/KEYNOTE-483 trial identifies a statistically significant survival benefit with pembrolizumab and chemotherapy vs chemotherapy alone in the first-line setting for patients with unresectable advanced or metastatic malignant pleural mesothelioma.
SBRT Provides Positive Locoregional Control in Lung Neuroendocrine Tumors
February 9th 2023Data from a retrospective study suggests that stereotactic body radiotherapy may be a suitable alternative to surgical resection for patients with primary lung neuroendocrine tumors, according to an expert from Moffitt Cancer Center.
Joel W. Neal, MD, PhD Discusses the Data on Cabozantinib and Atezolizumab Use in Advanced NSCLC
September 28th 2022In terms of tumor control, treatment with cabozantinib and atezolizumab led to an overall response rate of 19% among patients with advanced non–small cell lung cancer, according to Joel W. Neal, MD, PhD.
Study Finds Particulate Matter May Drive EGFR-Positive Non-Small Cell Lung Cancer
September 10th 2022Findings provided rationale to limit air pollution and highlighted the need for molecularly targeted lung cancer prevention due to particulate matter being revealed as a mechanistic driver for EGFR-positive NSCLC.